RESEARCH PAPER

A meta-analysis of the efficacy of over-the-counter nicotine replacement

J R Hughes¹, S Shiffman², P Callas³, J Zhang³

¹ Department of Psychiatry, University of Vermont, Burlington, Vermont, USA
² Pinney Associates and the University of Pittsburgh, Pittsburgh, Pennsylvania, USA
³ Medical Biostatistics, University of Vermont

Correspondence to:
Correspondence to: John R Hughes, MD, University of Vermont, Department of Psychiatry, 38 Fletcher Place, Burlington, VT 05401, USA; john.hughes{at}uvm.edu

Objective: To determine whether over-the-counter (OTC) nicotine replacement therapy (NRT) is pharmacologically efficacious, whether it produces abstinence rates similar to those in prescription settings, and to estimate the long term (that is, greater than six month) abstinence rate with OTC NRT.

Method: Systematic literature review.

Data sources: Medline, Psych Abstracts, bibliographies, requests of scientists.

Study selection: Studies comparing OTC NRT versus OTC placebo or studies comparing OTC NRT versus prescription NRT that reported abstinence rates and for which a full study report was available.

Data extraction: Two of the authors independently reviewed studies and compared results.

Data synthesis: Meta-analysis was performed by first testing for homogeneity across studies, then combining odds ratios (ORs) weighting by inverse variance and proportions weighting by study sample size.

Results: One OTC NRT versus OTC placebo nicotine gum study was excluded due to small sample size and different setting. The four remaining studies were randomised trials of nicotine versus placebo patch with ORs of 2.1–3.2. These outcomes were homogenous and when combined resulted in an OR favouring NRT of 2.5 (95% confidence interval (CI) 1.8 to 3.6). Among the two randomised and two non-randomised trials of OTC NRT versus prescription NRT, one small study had an OR of 0.3, two others had ORs of 1.0 and 1.4, and a fourth study had an OR of 3.6. These results were not homogenous; however, when combined via a random effects model the estimated OR was not less than 1.0—that is, OR 1.4 (95% CI 0.6 to 3.3). The long term (that is, greater than six months) quit rates for OTC NRT was 1% and 6% in two studies and 8–11% in five other studies. These results were not homogenous; however, when combined the estimated OR was 7% (95% CI 4% to 11%).

Conclusions: OTC NRT is pharmacologically efficacious and produces modest quit rates similar to that seen in real world prescription practice.

Keywords: meta-analysis; nicotine; nicotine gum; cessation; tobacco use disorder; transdermal nicotine

Abbreviations: CI, confidence interval; NRT, nicotine replacement therapy; OTC, over-the-counter; OR, odds ratio

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Amodei, N., Lamb, R. J. (2009). The role of nicotine replacement therapy in early quitting success. Nicotine Tob Res 0: ntp164v1-ntp164 [Abstract] [Full Text]  
• Tworek, C., Haskins, A., Woods, S. (2009). Maine's Tobacco Medication Program: Compliance, patterns of use, and satisfaction among smokers. Nicotine Tob Res 11: 904-907 [Abstract] [Full Text]  
• Van Zundert, R. M. P., Boogerd, E. A., Vermulst, A. A., Engels, R. C. M. E. (2009). Nicotine withdrawal symptoms following a quit attempt: An ecological momentary assessment study among adolescents. Nicotine Tob Res 11: 722-729 [Abstract] [Full Text]  
• Aveyard, P., Moore, D., Connock, M., Wang, D., Fry-Smith, A., Barton, P. (2009). Authors respond to criticism that treatment is ineffective. BMJ 338: b1979-b1979 [Full Text]  
• Hollis, J. F, McAfee, T. A, Fellows, J. L, Zbikowski, S. M, Stark, M., Riedlinger, K. (2007). The effectiveness and cost effectiveness of telephone counselling and the nicotine patch in a state tobacco quitline. Tobacco Control 16: i53-i59 [Abstract] [Full Text]  
• West, R., Zhou, X. (2007). Is nicotine replacement therapy for smoking cessation effective in the "real world"? Findings from a prospective multinational cohort study. Thorax 62: 998-1002 [Abstract] [Full Text]  
• Aveyard, P., Brown, K., Saunders, C., Alexander, A., Johnstone, E., Munafo, M. R, Murphy, M. (2007). Weekly versus basic smoking cessation support in primary care: a randomised controlled trial. Thorax 62: 898-903 [Abstract] [Full Text]  
• Etter, J.-F., Stapleton, J. A (2006). Nicotine replacement therapy for long-term smoking cessation: a meta-analysis.. Tobacco Control 15: 280-285 [Abstract] [Full Text]  
• Lee, A. M., Tyndale, R. F. (2006). Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. J Psychopharmacol 20: 7-14 [Abstract]  
• Shiffman, S, Di Marino, M E, Sweeney, C T (2005). Characteristics of selectors of nicotine replacement therapy. Tobacco Control 14: 346-355 [Abstract] [Full Text]  
• Shiffman, S, Hughes, J R, Pillitteri, J L, Burton, S L (2003). Persistent use of nicotine replacement therapy: an analysis of actual purchase patterns in a population based sample. Tobacco Control 12: 310-316 [Abstract] [Full Text]  
• Marcovitch, H. (2003). BMJ family highlights. BMJ 326: 1005-1005 [Full Text]  

eLetters:

Read all eLetters

OTC NRT 93% Midyear Relapse Rate

John R. Polito

Tobacco Control Online, 6 Mar 2003 [Full text]

Re: OTC NRT 93% Midyear Relapse Rate

Saul Shiffman, et al.

Tobacco Control Online, 10 Mar 2003 [Full text]

Re: Re: OTC NRT 93% Midyear Relapse Rate

John R. Polito

Tobacco Control Online, 11 Mar 2003 [Full text]